Rush University Medical Center

EATONTOWN, N.J., Oct. 28, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Christopher C. Gillis, MD, FRCSC, FAANS is acknowledged as a Pinnacle Professional Member Inner Circle of Excellence for his contributions in Revolutionizing Spine Surgery with Minimally Invasive Techniques. Continue Reading Christopher C Gillis MD FRCSC FAANS Dr. Christopher C. Gillis, MD, FRCSC, FAANS, a prominent leader in spine surgery, is redefining the landscape of spinal health with his innovative approach to minimally invasive spine treatments and advanced spine navigation. Known for his expertise in motion-sparing spine treatments and spine deformity corrections, Dr. Gillis is at the forefront of a transformative era in spinal healthcare. Dr. Gillis's journey in medicine began with a Bachelor of Science in Biology from Dalhousie University, followed by an MD from the Schulich School of Medicine at the University of Western Ontario in 2008. His residency at the University of British Columbia laid a strong foundation for his career, which was further enhanced by advanced training in minimally invasive and complex spine surgery through a clinical fellowship at Rush University Medical Center in Chicago. His educational background equips him with a comprehensive understanding of spine surgery, from fundamental principles to cutting-edge techniques. As a Fellow of the Royal College of Surgeons of Canada (FRSCS) and the American Association of Neurological Surgeons (FAANS), Dr. Gillis is deeply involved in professional circles dedicated to advancing neurological and spinal health. His affiliations with the Congress of Neurological Surgeons (CNS) and its Spine and Peripheral Nerve subsection reflect his commitment to staying at the forefront of his field. Dr. Gillis has distinguished himself through pioneering work in minimally invasive spine techniques and his specialization in addressing spine deformities with minimal surgery. His dedication to advancing surgical methods is evident in his role as Spine Programs Medical Director and Assistant Professor at the Division of Neurosurgery, University of Nebraska Medical Center. Additionally, he serves as a Clinical Assistant Professor in the Department of Neurosurgery at New York University, where he contributes to the education and training of future neurosurgeons. With 26 peer-reviewed publications, 16 book chapters, and 12 international presentations, Dr. Gillis is recognized globally for his contributions to spine surgery. His research and insights are pivotal in shaping the future of spinal health, and his work continues to inspire and inform the medical community. Dr. Gillis's personal interests include playing bass guitar in a classic rock band, showcasing his diverse talents and interests beyond the operating room. His mentors, Dr. Dvorjak, Dr. Fessler, and Dr. Traynelis, have been instrumental in his professional development, guiding him towards excellence in his field. Married to Estelle, Dr. Gillis is grateful for her unwavering support throughout his career. As he looks to the future, Dr. Gillis remains dedicated to furthering advancements in minimally invasive spine surgery and spine robotics, always with a focus on achieving the best results with minimal intervention. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024, in Barcelona, Spain. Gary Steinberg, MD, Professor of Urology, Department of Urology, Rush University Medical Center, will be joining members of TYRA's management team on the call and will be available during Q&A. Conference Call Information TYRA is hosting a conference call and webcast on October 25, 2024, at 8am ET to review the interim clinical data demonstrated with TYRA-300 in mUC. Participants may access a live webcast of the call and the associated slide presentation on the "For Investors" page of the TYRA website at . To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 90 days. About Tyra Biosciences Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA. For more information about our science, pipeline and people, please visit and engage with us on LinkedIn. Contact: Amy Conrad [email protected] SOURCE Tyra Biosciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NPC is a progressive disease where the patient has a mutation in NPC1 or NPC2 – genes that are involved in the processing of cholesterol and other lipids inside cells. Cells with this mutation have a faulty management of lipids, leading to organ damage and neurological symptoms including difficulty with speech and cognition. Delivered as an oral treatment three times per day, Miplyffa boosts the activity of two proteins in the cell called transcription factors EB (TFEB) and E3 (TFE3). These proteins upregulate genes encoding proteins that help lipids within cells to return to healthy levels. Miplyffa is specifically approved for use in combination with miglustat, a drug that is used off-label to treat NPC in around 80% of patients in the U.S. Miplyffa was approved based on results from a phase 2 trial where the drug slowed the progression of NPC compared to patients given a placebo. The company plans to launch the drug within 12 weeks of its approval and expects to set an average price of $85,000 per month for each patient, said president and CEO of Zevra Therapeutics Neil McFarlane in a public conference call ​. At the same time, Zevra launched a patient support program called AmplifyAssist to help patients and carers with personalized insurance coverage education and assistance with finding funding for their needs. “The FDA approval of Miplyffa marks a significant moment for those living with NPC and the global NPC community,” stated ​ Elizabeth Berry-Kravis, professor at Rush University Medical Center, who worked with Zevra to research Miplyffa use in a real-world setting. She added that effective NPC treatment “requires multiple treatment options due to the complexity of the disease” and that “patients will now have more access to treatments to tackle this devastating disease.” googletag.cmd.push(function () { googletag.display('text-ad1'); }); Arimoclomol was previously developed by the Danish company Orphazyme, which rose to fame ​ in 2021 as a so-called ‘meme’ stock whose price was influenced by social media. In the same year, Orphazyme was slapped with a rejection of arimoclomol from the U.S. FDA in 2021, with the regulator requesting more data. Grappling with bankruptcy, Orphazyme sold its assets to Zevra (then known as KemPharm) in 2022 ​ for $12.8 million. Another candidate in development is IntraBio’s small molecule therapy which is being reviewed by the U.S. FDA with a decision expected in the coming days. And the Dutch company Azafaros is taking its candidate nizubaglustat into phase 3 testing in patients with a genetic diagnosis of either GM2 gangliosidosis or NPC next year ​.